Jennifer O'Sullivan
@jm_osullivan
Followers
304
Following
569
Media
2
Statuses
177
DPhil Student @MRC_WIMM, MRC-Leukaemia UK Clinical Research Fellow @The_MRC @LeukUK, Haematologist, Corkonian, trail runner
London, England
Joined April 2010
Really excited that the molecular analysis of high-risk MAJIC-ET cohort is now online @BloodJournal. Big thank you to @AdamMead_Oxford @harrisoncn1 @ChristinaBYap @SoniaFox_TAP Angela Hamblin & collaborators for bringing this important work together! https://t.co/pA8lTusGN4
#MPN
2
8
32
MPN Voice news - survey for a proposed study of molecular monitoring in MPN patients. @MPNSM @MPNVoice @jm_osullivan Calling all MPN patients please give us your views on this new study !
0
13
19
Honoured to be elected as a Fellow of the Academy of Medical Sciences @acmedsci. Credit goes to the talented scientists and clinicians I have had the pleasure to work with & amazing fellowship support since joining the @MRC_WIMM in 2008 from @CRUKresearch @bloodcancer_uk @The_MRC
19
3
75
We are very excited to present the development of Zman-seq (“Zman”, Hebrew for “time”), the 1st technology that measures single-cell transcriptomes and physical time in vivo, led by @D_Birschenkaum, @CuriousKX, @FlorianIngelfi1, @AssafWeiner
https://t.co/pDk6ackAtV. (1/19)
43
285
915
1 week left to apply to join us in Oxford for a CAR-T fellowship! Be part of our expanding CAR-T team for a dynamic journey 🚀 📆 1-year program 🏫Oxford-based 🧬 Advanced Cellular Therapies Apply here ⬇️ https://t.co/4JwQUuYmIs
0
20
34
Excellent posters from @Sean_Wen221 and @jm_osullivan at @ASH_hematology #ASH23. They are both superstars and lovely people to work with. Although looks like I am doing a product placement for @dosdesperados beer!
0
2
27
Heading home from #ASH23? 👩💼🌞🌮Stuck in a line at security or facing a long layover? ✈️In withdrawal from all the amazing science? 🧪🧬 Read our preprint from my PhD work @UniofOxford @MRC_WIMM presented in the MPN session yesterday! https://t.co/uH3dzJ5ueD 1/n
biorxiv.org
Chromothripsis, the process of catastrophic shattering and haphazard repair of chromosomes, is a common event in cancer. Whether chromothripsis might constitute an actionable molecular event amenable...
6
22
105
Incredibly proud of the team who will be presenting 6 abstracts today (4 oral presentations and two posters). Hope you will be able to catch some of them. I will be putting on my running shoes to get between the sessions in good time! Might need this too (Harry Potter ref):
3
7
54
@MPNSM @jm_osullivan @AdamMead_Oxford @ASH2023 Great talk from Jen O’Sullivan summarising beautifully her work on SF3B1 in JAK2 positive MPN
0
1
9
Christina Simoglou-Karali delivering a super clear presentation.
0
3
18
Want somethg exciting & totally new at #ASH2023 @ASH_hematology? Check out @l_cmurphy @MRC_WIMM 's talk Sat 4PM SDCC-Rm 33. Beautiful imaging, whole genome sequencing & fx analysis of platelets exploring how they sequester free fetal and cancer-derived DNA https://t.co/yrEklMT9DE
3
13
65
🛎️ 🚨 👉🏼👉🏼Companion paper now published - newly updated @BritSocHaem guidance on the Management of Myelofibrosis! Thanks to absolutely everyone involved in bringing this together and @BrJHaem @MPNVoice! Link: https://t.co/njy0LQegxV
#mpnsm
onlinelibrary.wiley.com
Click on the article title to read more.
2
17
69
Terrific work by @jm_osullivan and team, in partnership with Cell Therapeutics. Jen analysed the genetic lanscape of pts with high risk myelofibrosis on the PAC203 study. Strikingly high-incidence of subclonal RAS pathway mutations (21%). https://t.co/AMO4tsPMEv
6
5
18
Super pleased to see that NICE has approved Ruxolitinib for PV in England !! @MPNVoice FDG published today. Let’s get on and test this drug in the front line as the Mithridate study being run jointly between 🇫🇷 and 🇬🇧 with @jjkiladjian
#MPNSM #MPN Awareness Day #MPN Voice Sending a message to all patients and wonderful colleagues on MPN Awareness Day! From the @GSTTnhs team!
6
15
97
Yesterday some of our staff walked to the National Windrush Monument at Waterloo station, to reflect on the experiences of the Windrush generation and to celebrate their contribution to society and the NHS. #TeamGSTT #Windrush75 Play the video to find out more:
1
10
54
Congratulations to Lauren (@l_cmurphy), Patrick, Jennifer (@jenniherrmann), and Anna, who have been shortlisted for the Ita Askonas Medal 🏅 and will give talks at #WIMMday2023 for the chance to win a prize of £500! 🎉
0
8
32
🔥🔥🔥🔥🔥🔥 MAJIC study published in @JCO_ASCO Ruxolitinib (rux) Versus Best Available Therapy (BAT) for Polycythemia Vera (PV) Intolerant or Resistant to Hydroxycarbamide (HC) in a Randomized Trial
ascopubs.org
PURPOSEPolycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts...
4
21
56
Two seminal papers from the @MRC_MHU @UniofOxford in one week! @YRMeng et al @NatureCellBio dissect the epigenetic regulation of HSC fate restriction and the relative contributions of HSC subsets to platelet production using elegant mouse models (1/2)
Excited to share that my postdoctoral work is finally out @NatureCellBio, thanks to all the great people @Simona66274422 @SThongjuea I've been working with @UniofOxford @MRC_WIMM. What a journey! https://t.co/GI3Q00k0pw
2
5
29
Amazing to see ruxolitinib improves outcomes for patients with polycythaemia vera! Huge thanks to all those involved in the MAJIC🪄 trial! @CRCTU @harrisoncn1 @AdamMead_Oxford @ChristinaBYap @jyoti_nangalia @jm_osullivan @mpdrc @JoannaBaxter99 @bloodcancer_uk
📢The drug ruxolitinib has been found to be better at treating the blood cancer polycythaemia vera than the best currently available treatment in those intolerant or resistant to Hydroxycarbamide in a randomized phase II trial Read more 👇 https://t.co/ubthLDuFW0
0
1
6
Introduction to a review series on single-cell genomics: getting ready for clinical impact in leukemia and myeloid neoplasms
0
4
10